Cardiovascular Disease

Patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM) are at risk of cardiovascular comorbidities, including atrial fibrillation and flutter. Routine ambulatory monitoring in patients with ATTR-CM could help drive the use of anticoagulation to prevent strokes. Heart…

Heart failure, among other cardiovascular problems, is a typical manifestation of transthyretin amyloidosis cardiomyopathy (ATTR-CM). The prevalence of ATTR-CM as a phenotype of heart failure is often underestimated. Heart failure with preserved ejection fraction (HFpEF)…

Medication adherence is a critical aspect of treating patients with ATTR-CM and ensuring optimal outcomes. Research suggests that many patients with ATTR-CM are adherent to treatment with tafamidis, partly due to the availability of a…

An early diagnosis of transthyretin amyloidosis (ATTR) is key for managing the disease and preventing costly complications. One study suggests that cardiovascular symptoms and increased hospitalizations are a potential way to identify the disease early.…

Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are faced with different possibilities for treating their symptoms and underlying disease. However, treatment options may vary depending on the severity of the disease, the cost of the treatment,…